|
Solvent |
mg/mL |
mM |
Solubility |
DMSO |
25.0 |
97.00 |
Ethanol |
2.0 |
7.80 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
257.76
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yap KY, Tay WL, Chui WK, Chan A. Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care (Engl). 2009 Dec 17. [Epub ahead of print] PubMed PMID: 20030690.
2: Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, Kaina B. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst). 2009 Jan 1;8(1):72-86. Epub 2008 Oct 21. PubMed PMID: 18840549.
3: Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009 Apr 2;113(14):3307-13. Epub 2008 Sep 3. PubMed PMID: 18768784.
4: Krawczuk-Rybak M, Leszczyńska E, Wysocka J, Zelazowska-Rutkowska B. [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer]. Pediatr Endocrinol Diabetes Metab. 2008;14(2):99-103. Polish. PubMed PMID: 18721496.
5: Glen CD, Smith AG, Dubrova YE. Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice. Cancer Res. 2008 May 15;68(10):3630-6. PubMed PMID: 18483245.
6: Gasowska-Bajger B, Wojtasek H. Indirect oxidation of the antitumor agent procarbazine by tyrosinase--possible application in designing anti-melanoma prodrugs. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3296-300. Epub 2008 Apr 22. PubMed PMID: 18457951.
7: Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007 Jun;3(2):213-24. PubMed PMID: 18360630; PubMed Central PMCID: PMC1936303.
8: Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 1;12(17):5174-81. PubMed PMID: 16951236.
9: Giordana MT, Ghimenti C, Leonardo E, Balteri I, Iudicello M, Duò D. Molecular genetic study of a metastatic oligodendroglioma. J Neurooncol. 2004 Feb;66(3):265-71. PubMed PMID: 15015656.
10: Ewesuedo RB, Dolan ME. Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol. 2000;46(2):150-5. PubMed PMID: 10972485.